What is Imaginostics?
Imaginostics is at the forefront of developing non-invasive diagnostic tools that leverage breakthrough quantitative imaging biomarkers. Their proprietary technology seamlessly integrates with existing MRI scanners, enabling enhanced visualization of vasculature, comprehensive health assessments, and early disease detection. The company is actively engaged in pre-clinical and clinical research across critical fields such as neuroscience, oncology, and cardiology. By seeking strategic partnerships with academic investigators, Imaginostics aims to accelerate the translation of its safe and effective imaging technology into clinical practice, thereby improving patient outcomes.
How much funding has Imaginostics raised?
Imaginostics has raised a total of $6.6M across 4 funding rounds:
Multiple Rounds
$6.6M
Private Equity (2026): $5.4M, investors not publicly disclosed
Private Equity (2026): $500K, investors not publicly disclosed
Private Equity (2026): $726K, investors not publicly disclosed
Private Equity (2026): $40K, investors not publicly disclosed
What's next for Imaginostics?
With the infusion of substantial expansion capital, Imaginostics is poised for a significant growth phase. The company's focus on developing imaging solutions compatible with existing MRI infrastructure positions it favorably to capture a broad market share. Future strategic initiatives will likely involve scaling up research and development efforts, expanding clinical trials across its target areas of neuroscience, cancer, and cardiology, and forging key collaborations with healthcare institutions and pharmaceutical companies. This latest investment will be instrumental in advancing their pipeline and bringing their innovative diagnostic capabilities to a wider patient population, solidifying their role in the future of medical imaging.
See full Imaginostics company page
